Top

Published in:

01-03-2011

Two BRCA1/2 founder mutations in Jews of Sephardic origin

Authors: Michal Sagi, Avital Eilat, Liat Ben Avi, Yael Goldberg, Dani Bercovich, Tamar Hamburger, Tamar Peretz, Israela Lerer

Published in: Familial Cancer | Issue 1/2011

Abstract

Founder mutations in BRCA1/2 genes have been detected in several Jewish communities in Israel, including in Ashkenazi Jews and Jews who immigrated to Israel from Iraq, Yemen, Iran and Afghanistan. We analyzed DNA samples of patients of Sephardic origin (descendents of Jews from the Iberian Peninsula) with breast cancer (BC) and/or ovarian cancer (OC) and additional family history of these cancers. In this study we identified 2 mutations: p.A1708E in BRCA1 and c.67 + 1G > A (IVS2 + 1G > A) in BRCA2, each in 3 unrelated patients. The frequency of the two mutations was 26–31% among Sephardic high risk families and about 3% among the full cohort of 177 patients of this origin who were tested in our center. Based on haplotype analysis we concluded that these mutations are most probably founder mutations in Sephardic Jews. We recommend testing the two mutations in women of Sephardic origin who apply for BRCA testing because of personal and/or family history of BC and/or OC. Furthermore, we suggest adding them to the 5 mutations included in “The Jewish panel” of BRCA1/2 mutations that are being tested in Israel.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505–514PubMed

Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272–274CrossRefPubMed

Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E (2001) The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. Community Genet 4:50–55CrossRefPubMed

Ben-Sasson HH (ed) (1976) A history of the Jewish People. Harvard University Press, Cambridge, Massachusetts

Bercovich D, Beaudet AL (2003) Denaturing high-performance liquid chromatography for the detection of mutations and polymorphisms in UBE3A. Genet Test 7:189–194CrossRefPubMed

Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi93–vi98

Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brøndum-Nielsen K, Gerdes AM, Møller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN (2001) Functional analysis of BRCA1 C terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353–560CrossRefPubMed

Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, Arnold S, Buchanan D, kConFab Investigators, Couch FJ, Henderson BR, DE Goldgar, Tavtigian SV, Chenevix-Trench G, Brown MA (2007) dentification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9:R82CrossRefPubMed

de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97:466–471CrossRefPubMed

10.

Infante M, Durán M, Esteban-Cardeñosa E, Miner C, Velasco E (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet 51:611–617CrossRefPubMed

11.

Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225–232CrossRefPubMed

12.

Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, Sensi E, Falaschi E, Cipollini G, Bevilacqua G, Caligo MA (2006) RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genetics and Cytogenetics 170:93–101CrossRefPubMed

13.

Breast Cancer Information Core:http://www.genome.gov/

14.

Cohen T, Vardi-Saliternik R, Friedlander Y (2004) Consanguinity, intracommunity and intercommunity marriages in a population sample of Israeli Jews. Ann Hum Biol 31:38–48CrossRefPubMed

Title: Two BRCA1/2 founder mutations in Jews of Sephardic origin
Authors: Michal Sagi
Avital Eilat
Liat Ben Avi
Yael Goldberg
Dani Bercovich
Tamar Hamburger
Tamar Peretz
Israela Lerer
Publication date: 01-03-2011
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 1/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9395-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Genetic epidemiological analysis reveals a multi-gene additive model for gastric cancer

Strictly defined familial male breast cancer

Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis

Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis

A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history

Hereditary prostate cancer as a feature of Lynch Syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer